Cost‐effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India
Explore this paper's citation graph
Summary
To assess the cost‐effectiveness of current monotherapies and prospective combinations for treating visceral leishmaniasis in Bihar, India in terms of years of life lost (YLL) averted as well as deaths averted.
- Type
- article
- Published
- 2009-08-01
- Cited by
- 60
- References
- 16
- OpenAlex
- https://openalex.org/W1966822741
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:29278489
Keywords
Medicine, Years of potential life lost, Visceral leishmaniasis, Disability-adjusted life year, Cost effectiveness
References
- Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management
- Epidemiology of visceral leishmaniasis in India.
- Chemotherapy in the treatment and control of leishmaniasis.
- Cost-effectiveness in health and medicine
- Tropical Diseases Lacking Adequate Control Measures: Dengue, Leishmaniasis, and African Trypanosomiasis -- Disease Control Priorities in Developing Countries
- Liposomal amphotericin B in the treatment of visceral leishmaniasis.
- Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India
- Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.
- Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis.
- Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004.
- Drug policy for visceral leishmaniasis: a cost‐effectiveness analysis
- New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
- In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs
- Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India
Cited by
- Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.
- Selection of novel antigens from Leishmania spp. and design of live recombinant salmonella vaccines against experimental visceral leishmaniasis
- A Systematic Review of the State of Economic Evaluation for Health Care in India
- Health Economic Evaluations of Visceral Leishmaniasis Treatments: A Systematic Review
- Drug combinations for visceral leishmaniasis
- Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)
- Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
- Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans
- Socio–economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis
- Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasis
- Live Vaccination Tactics: Possible Approaches for Controlling Visceral Leishmaniasis
- Options for Active Case Detection of Visceral Leishmaniasis in Endemic Districts of India, Nepal and Bangladesh, Comparing Yield, Feasibility and Costs
- Poly(methacrylic acid) complexation of amphotericin B to treat neglected diseases
- Assessing the Quality of Pharmacoeconomic Studies in India
- Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
- Noncovalent complexation of amphotericin-B with Poly(α-glutamic acid).
- Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent
- Clinical pharmacology in leishmaniasis: treatment optimization of a neglected disease
- Antileishmanial Activity, Uptake, and Biodistribution of an Amphotericin B and Poly(α-Glutamic Acid) Complex
- Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia.
Related papers
- Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)
- Post-Kala-Azar Dermal Leishmaniasis in a Patient Treated with Injectable Paromomycin for Visceral Leishmaniasis in India
- Efficacy and Safety of Paromomycin for Visceral Leishmaniasis: A Systematic Review
- Visceral leishmaniasis (kala-azar): challenges ahead.
- A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy
- Leishmaniasis
- Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
- Current treatment of visceral leishmaniasis (Kala-azar): an overview
- Current diagnosis and treatment of visceral leishmaniasis
- Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?